About: A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 15 May 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в травні 2009 (uk) scientific article published on 15 May 2009 (en) مقالة علمية نشرت في 15 مايو 2009 (ar)
publication date	wds:Q37294887-42F0F111-9EC9-40AE-BEFD-4B8732433128
publication date	2009-05-15 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37294887-24EF399E-BB17-4733-895E-3BAD2F7773B1
language of work or name	English
cites work	wds:Q37294887-022536C0-0456-49D9-8E2A-A8909DC5B8D6 wds:Q37294887-0CCF5E91-E9F9-4C0F-A375-6E6D9843C049 wds:Q37294887-0F0B747C-988D-4650-82BC-9BEE192E86B0 wds:Q37294887-16DC335A-441B-46A9-BB5E-A172CE52CDA0 wds:Q37294887-18762201-07E5-405C-A490-1E8F65C6935A wds:Q37294887-1945E62B-B82B-40F5-9C3E-27332E4CBE67 wds:Q37294887-1CACB890-1E6C-43BB-B32F-543385B111A5 wds:Q37294887-30D6AB56-8AD3-4C10-9EE2-1AF864854556 wds:Q37294887-344386FF-6E54-4B5E-A4CB-2120E3A30F3F wds:Q37294887-3F3F7DBA-CEA9-49B3-922B-38016A8841DD wds:Q37294887-44ED7766-EA23-44BB-BE23-EFA82B822C18 wds:Q37294887-4EE1528B-4F13-4F7E-BB91-2F3441F41D70 wds:Q37294887-65C6A289-3E97-42FC-BA08-07629BCED5EF wds:Q37294887-68FC0B65-3B15-4DD4-812E-6E5DD8F0C4E7 wds:Q37294887-6A478F01-87FE-4A84-A7DC-EDBA5AC03E54 wds:Q37294887-8A99F6B3-CC14-40DC-8E56-CE5C8FAF1AA0 wds:Q37294887-94CF8B5B-B9B5-45EE-B2E4-0FB3F5E101E5 wds:Q37294887-B28C4DB2-BF10-4B77-B399-D94911FA3FE5 wds:Q37294887-B9705DB2-106B-4CD9-93B1-2AF348B57593 wds:Q37294887-C4830380-C193-4E66-B290-CC75DE3A67A2 wds:Q37294887-C4B069FE-EDA9-4D3E-BD2E-0E8E939F402F wds:Q37294887-C932E284-662A-4702-9E94-4415AD1A13BE wds:Q37294887-D2C46965-A279-40CC-ACF3-1581863EE71D wds:Q37294887-E96CA528-0944-4042-8043-41D0E3A7FF06 wds:Q37294887-EECEA0F9-1B3C-4CC6-88BB-5598D5554D24 wds:Q37294887-FCDDCC4C-A24A-4C9B-9021-364277962574 wds:Q37294887-FDDC0181-BF21-4FD2-8FF8-3C692D586F10 wds:Q37294887-FEEDC171-900B-491C-B9F8-DA37E7F18699
cites work	Vaccination of infants with a four-dose and a three-dose vaccination schedule Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses Apical membrane antigen 1: a malaria vaccine candidate in review Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response Structural basis of antigenic escape of a malaria vaccine candidate Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial Transmission-blocking vaccines. STUDIES ON ANTIBODY PRODUCTION. XI. VARIATION IN THE SECONDARY RESPONSE AS A FUNCTION OF THE LENGTH OF THE INTERVAL BETWEEN TWO ANTIGENIC STIMULI Formulation of vaccines containing CpG oligonucleotides and alum Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Estimates of Location Based on Rank Tests Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine Malaria vaccines: are we getting closer? Random marginal agreement coefficients: rethinking the adjustment for chance when measuring agreement. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites.
author name string	wds:Q37294887-48373140-20B3-4FD0-877A-08038DF5C9CD
author name string	Laura B Martin
rdfs:label	A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. (nl) A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals (en) A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals (ast)
skos:prefLabel	A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. (nl) A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals (en) A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals (ast)
name	A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. (nl) A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals (en) A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals (ast)
author	wds:Q37294887-09BB4649-CDBA-4A38-9F61-EA577BD3F4F6 wds:Q37294887-1745AD04-AFCA-4206-A188-8C8FCDD9C15A wds:Q37294887-528028B6-8524-4240-863F-5C04CFBE5D14 wds:Q37294887-597B7E66-0F75-48BD-B07F-925886C3CB64 wds:Q37294887-6C80F5C2-DA55-4FF2-8A01-C2DCA8EA6062 wds:Q37294887-9058B316-5D69-4A6F-BC25-941522A70065 wds:Q37294887-94CA941E-9244-410A-8852-5014D650B187 wds:Q37294887-97809C63-894F-458D-81D9-C803F2BDEC26 wds:Q37294887-A99584C5-CECE-4478-BC48-5FB727B9A092 wds:Q37294887-E8F79611-254D-461F-9788-DD080262FA61
author	Louis H. Miller Donna Shaffer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software